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QALY and per LYG for XELOX/FOLFOX4CET. CONCLUSIONS: As a result of cost
analysis it was identified anticancer schemes, requiring the lowest and highest
costs. The account of CER, Markov’s model construction have demonstrated the
benefits of using XELOX/FOLFOX4BV regimes in patients with mCRC.
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OBJECTIVES: To perform a cost-effectiveness analysis comparing nanoparticle al-
bumin bound (nab) paclitaxel (N-P, 260 mg/m2) with solvent-based paclitaxel (S-P,
175 mg/m2) given every 3 weeks as second-line treatment for metastatic breast
cancer (MBC) from the perspective of the Portuguese National Health System
(PNHS). METHODS: A Markov type stochastic process including disease states pro-
gression-free, progressive disease and death was designed to model long-term
effectiveness and costs. Patient level data from a randomized, open-label, phase III
study (n460) was used to estimate parametric survival models (weibull) for time
to treatment discontinuation, time to progression and time to death. Effectiveness
was measured in life years (LY). Only direct costs were considered (drugs, medical
visits, hospitalization, adverse events (grade 3/4) treatment and monitoring, termi-
nal care). The source for unit costs was the PNHS price list. Time horizon was fixed
at 4 years. Probabilistic sensitivity analysis was conducted with Monte Carlo sim-
ulations. Discount rates of 5%/year were applied to costs and effectiveness.
RESULTS: A mean gain of 25 LY (95%CI: [2; 46]) was estimated for each 100 patients
treated with N-P. This would represent an average 22% life expectancy increment.
The estimated mean incremental cost of N-P treated patients was 7370 € (95%CI:
[6762; 7945]). Corresponding average incremental cost-effectiveness ratio was
29,535€/LY. Probabilistic sensitivity analysis revealed an 83% probability of N-P to
be cost-effective in comparison with S-P, at the commonly accepted threshold of
50,000€. CONCLUSIONS: nab-Paclitaxel may be considered a cost-effective drug as
it adds a substantial relative increment in the overall survival over second-line
solvent -based paclitaxel monotherapy in women with metastatic breast cancer.
The estimation of long-term benefits of nab-Paclitaxel beyond the clinical trial
follow-up period by Markov based modelling can provide valuable support to de-
cision making in the context of scarce resources.
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OBJECTIVES: Over the past decades, research focusing on new chemotherapeutic
agents for patients with inoperable NSCLC have reported only modest gains in
survival. These health gains are achieved at considerable costs, but economic ev-
idence on superiority of one of the agents in terms of cost-effectiveness is lacking.
The objective of this systematic review is to assess fully published cost-effective-
ness studies comparing the new agents docetaxel, paclitaxel, vinorelbine, gemcit-
abine and pemetrexed, and the targeted therapies erlotinib and gefitinib among
each other. METHODS: PubMed, EMBASE.com and Economic Evaluations (via the
Cochrane Library, Wiley) were systematically searched for fully published studies
from the past 10 years. Studies were screened by two independent reviewers ac-
cording to a priori inclusion criteria. The methodological quality of the included
studies was evaluated by two independent reviewers using standardized assess-
ment tools. RESULTS: A total of 222 potential studies were identified. Eleven cost-
effectiveness or cost-utility studies were included. The methodological quality of
the full economic evaluations was fairly good. Transparency in costs and resource
use, details on statistical tests and sensitivity analysis were points for improve-
ment. In first-line treatment, one study indicated that gemcitabine-cisplatin was
cost-effective compared to paclitaxel-based regimens, and another study indicated
that gemcitabine-cisplatin was cost-effective compared to platinum-based regi-
mens containing either paclitaxel, vinorelbine or docetaxel in terms of progres-
sion-free survival. In a third study, pemetrexed-cisplatin was cost-effective com-
pared to gemcitabine-cisplatin in patients with nonsquamous cell carcinoma. In
second-line treatment, docetaxel was cost-effective compared to BSC (range of
ICERs per LYG: US$22,190-US$32,133). Erlotinib was cost-effective compared to pla-
cebo in one study (ICER per LYG: US$33,728). Docetaxel and pemetrexed were dom-
inated by erlotinib in one study and in two studies, respectively. CONCLUSIONS:
We found indications for superiority in terms of cost-effectiveness of gemcitabine-
cisplatin in a first-line setting and for erlotinib in second-line setting.
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OBJECTIVES: To evaluate whether the use of bevacizumab  paclitaxel offers best
cost-effective results regarding the use of paclitaxel for patients with metastatic
breast cancer mBC METHODS: The treatment was evaluated up to the progression
of the disease, rescue management and palliative up to to death in a Markov model,
operating 65 cycles of 28 days. An incremental cost effectiveness analysis and
sensitivity analysis was performed considering as an outcome measure progres-
sion-free survival (PFS), on the cohort of 2000 patients with Her2 Ne mBC negative
and a subanalysis of the populations of patients with triple negative of patients
with Her2 Neu Negative, taking into account direct medical costs and social costs
due to premature death, in a horizon of 5 years (discount rate 5%). RESULTS: The
40.35% of patients survived after 12 months using bevacizumab paclitaxel, while
only 35.20% did so with only administered paclitaxel. 59.6% of these patients were
PFS with combination therapy, while 37.71% did with monotherapy. Combined
therapy provides more effectiveness than monotherapy in terms of overall sur-
vival, progression-free survival (PFS) and therapeutic response The incremental
cost of bevacizumab  paclitaxel is $7529 USD obeying the PFS difference in time
between the two cohorts, and higher consumption on the combination versus
monotherapy. For triple negative subpopulation, the ICER is $1793 USD while for
the sub-population of HER 2 is $1448 USD. The ICER is compared against a threshold
of 3 times GDP per capita in Mexico. The ICER is lower than the threshold, so it is
cost-effective CONCLUSIONS: The combination of bevacizumab  paclitaxel, for
all cases studied, represents a better alternative cost effective versus paclitaxel
monotherapy.
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OBJECTIVES: Chemotherapy induced nausea and vomiting (CINV) is a common
and distressing adverse effect of cancer chemotherapy. Despite the widespread use
of prophylactic anti-emetic agents, control of CINV induced by moderately emeto-
genic chemotherapy (MEC) remains sub-optimal, with breast cancer patients rep-
resenting a sub-population at increased risk. The aim of this analysis was to eval-
uate the cost-effectiveness of an aprepitant regimen compared to current clinical
practice in Scotland for the prevention of CINV in breast cancer patients receiving
MEC. METHODS: A decision-analytic model was developed to estimate the costs
and health outcomes associated with the prevention of CINV over a single chemo-
therapy cycle with a time horizon of 5 days post-chemotherapy. The analysis com-
pared an aprepitant regimen (aprepitant, ondansetron and dexamethasone pre-
chemotherapy, and aprepitant for 2 days following chemotherapy) to a commonly
used regimen in Scottish clinical practice (dexamethasone and ondansetron pre-
chemotherapy, and dexamethasone and domperidone for 2 days following chemo-
therapy). The health outcomes in the model were: complete protection (no emesis,
no rescue therapy and maximum nausea 25mm on VAS); complete response (no
emesis and no rescue therapy, but maximum nausea 25 mm); incomplete re-
sponse (some emesis or rescue therapy). Transition probabilities were based on a
randomised clinical trial comparing aprepitant and standard of care regimens,
which included 438 breast cancer patients. Chemotherapy among breast cancer
patients was comprised of anthracycline plus cyclophosphamide (AC) regimens
(87.2%) and non-AC regimens (12.8%). RESULTS:An aprepitant regimen when com-
pared to Scottish clinical practice for preventing CINV in breast cancer patients
receiving MEC is cost-effective with an incremental cost effectiveness ratio (ICER)
of £14,610 per QALY. CONCLUSIONS: Aprepitant is a cost-effective option for the
prevention of acute and delayed nausea and vomiting induced by MEC for the
treatment of breast cancer in Scottish clinical practice.
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OBJECTIVES: The adjuvant chemotherapy for stage III Colon Cancer is based in
oxaliplatin for 6 months. FOLFOX-4, FLOX and XELOX were very similar results in
efficacy and safety. There are some differences in total doses and form of the
application. We present the differences in direct and indirect costs of the 3
schemes in the National Cancer Institute (NCI) of Mexico. METHODS: We analyzed
130 patients with stage III Colon Cancer treated in the NCI of Mexico, from January
2004 to August 2010. The body surface mean was 1.62 and the costs were calculated
based on current prices-government in November 2010. We considered the follow-
ing costs: 1) Chemotherapy / BS , 2) Prophylactic anti-emetics, 3) Use of central
catheter (patients with XELOX, not used catheter), 4) Medical offices, 5) Laboratory
tests, 6) Adverse events grade 3-4 (used the frequency of reports of Andre T 2004/
FOLFOX, Kuebrer JP 2007/FLOX and Schomll HJ 2007/XELOX) and 7) Number of visits
to the Hospital and indirect costs at each visit (cost for visit was $ 39.68 US). All costs
was report in US dollars ($ 12.50 Mexican pesos  1 dollar US) RESULTS: The
estimated costs incurred by adjuvant chemotherapy regimen are reported as fol-
lows (FLOX, FOLFOX-4, XELOX): Chemotherapy ($13,349, $13,685, $15,365), Anti-
emetics ($326, $433, $288), Subclavian catéter-maintenance ($237, $237, $0), QT –
application ($764 $1,433, $352), Blood tests ($422, $563, $376), Medical offices ($405,
$527, $365), Adverse events grade 3-4 ($726, $568, $371), Hospital visits (number)
(40, 61, 17). Indirects costs for visit $1,587, $2,420, $675). The total cost of the treat-
ment is ($17,817, $19,866, $ 17,790). CONCLUSIONS: The FOLFOX scheme was more
expensive with the highest number of hospital visits. The scheme XELOX is more
practice, less expensive, less visit at the hospital and with less impact on lifestyle.
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